Exenatide
اگزناتاید
🍽️ Alimentary Tract And MetabolismGLP-1 receptor agonist
Market / country: 🇺🇸 USA
Byetta (US)
🧮 Dose calculator
Type 2 diabetes mellitus · Regimen source: FDA Byetta · 2.1
- • Do not inject after a meal. Never share a pen between patients. FDA Byetta · 2.1FDA Byetta · 5.2
Enter age (weight is optional for this regimen).
🛡️ Safety & information
Contraindications
- ⛔ Prior severe hypersensitivity to exenatide; history of drug-induced immune-mediated thrombocytopenia from exenatide products. FDA Byetta · 4
Warnings
- • Acute pancreatitis; hypoglycaemia with sulfonylureas or insulin; acute kidney injury from volume depletion; severe GI reactions; thrombocytopenia; gallbladder disease; pulmonary aspiration during anaesthesia. FDA Byetta · 5
Renal adjustment
- • eGFR < 30: CrCl <30 or ESRD: not recommended. FDA Byetta · 8.6
Formulations
- 250 mcg/mL prefilled pen (5 or 10 mcg per dose) — injection 🇺🇸 USA FDA Byetta · 3
👥 Special populations
- 🤰 PregnancyUse with caution
Label states no clear risk or has limited data; use only if needed, under medical advice. FDA Byetta · 8.1
“Risk Summary Limited data with BYETTA in pregnant women are not sufficient to determine a drug-associated risk for major birth defects or miscarriage.”
- 🤱 BreastfeedingUse with caution
Label: use with caution while breastfeeding; see the label text. FDA Byetta · 8.2
“Risk Summary There is no information regarding the presence of BYETTA, in human milk, the effects of BYETTA on the breastfed infant, or the effects of BYETTA on milk production.”
- 👶 ChildrenUse with caution
The label has conditions, age limits or notes for children; the label sentence is quoted below. FDA Byetta · 8.4
“The safety and effectiveness of BYETTA have not been established in pediatric patients.”
- 👴 Older adultsUse with caution
Label: use with caution in older adults, usually starting at the low end of the dose range. FDA Byetta · 8.5
“Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection in the elderly based on renal function.”
- ⚥ Females & males of reproductive potentialNo data
The source for this drug has no section for this group.
🔗 Reference links
- FDA (approval record)NDA021773
- DailyMed (FDA label)FDA Byetta
- MedlinePlus (NIH)Exenatide Injection
- WHO ATC/DDDA10BJ01
- Darooyab (Iran)Exenatide
🇮🇷 Registered in Iran Darooyab · G-4914/Exenatide
Dosage forms with Iranian generic codes, per Darooyab.
- 51329 · EXENATIDE INJECTION, SUSPENSION, EXTENDED RELEASE PARENTERAL 2 mg · فرآورده تزریقی اکسناتاید ۲ میلیگرم
📚 Reference status for this drug
Shows which sources have references recorded for this drug and which do not.
- FDA label (DailyMed)✅ PresentFDA Byetta · 3FDA Byetta · 2.1FDA Byetta · 5.2FDA Byetta · 4FDA Byetta · 5FDA Byetta · 8.6FDA Byetta · SPL approval / marketing categoryFDA Byetta · 8.1FDA Byetta · 8.2FDA Byetta · 8.4FDA Byetta · 8.5
- UK SmPC (eMC / MHRA)❌ Not present
- Published guideline❌ Not present
- Licensed reference (medical school)❌ Not present
- Iranian leaflet (IFDA)❌ Not present
- Pharmacy website (secondary, unreliable)✅ PresentDarooyab · G-4914/Exenatide
- Clinical review⚠ Unverified